BioNTech以3.62亿英镑收购InstaDeep，加强AI药物研发布局
WEB2023年1月10日，BioNTech SE（Nasdaq: BNTX）和 InstaDeep宣布，他们已达成协议，根据该协议，BioNTech将收购人工智能和机器学习领域的全球领先技术公司 InstaDeep。 该交易包括约3.62亿英镑的现金，收购InstaDeep剩余股份的100%，不包括BioNTech已拥有的
BioNTech Completes Acquisition of InstaDeep | BioNTech
WEBMAINZ, Germany, July 31, 2023 – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) announced today the completion of the acquisition of InstaDeep Ltd. (“InstaDeep”), a leading global technology company in the field of artificial intelligence (“AI”) and machine learning (“ML”).
BioNTech to Acquire InstaDeep to Strengthen Pioneering Position …
WEBJan 10, 2023 · BioNTech SE (Nasdaq: BNTX, “BioNTech”) and InstaDeep Ltd. (“InstaDeep”) today announced that they have entered into an agreement under which BioNTech will acquire InstaDeep, a leading global technology company in the field of artificial intelligence (“AI”) and machine learning (“ML”).
明看并购 | BioNtech：新春拥抱AI-经济观察网 - eeo
WEB2023年新春伊始，疫苗巨头BioNtech宣布以5.62亿欧元收购英国人工智能初创企业InstaDeep，其中3.62亿欧元预付款收购除BioNtech之外的剩余股权，基于业绩的未来里程碑付款最高可达约2亿欧元。. 本次收购创造了BioNtech迄今为止的最大收购交易，同时为AI制药类公司开了 ...
明看并购 | BioNtech：新春拥抱AI - 经济观察网 － 专业财经新闻 …
WEB2023年新春伊始，疫苗巨头BioNtech宣布以5.62亿欧元收购英国人工智能初创企业InstaDeep，其中3.62亿欧元预付款收购除BioNtech之外的剩余股权，基于业绩的 ...
5.62亿英镑！BioNTech收购AI公司InstaDeep - Pharmcube
WEB1月10日， BioNTech 和 InstaDeep 宣布已达成协议，BioNTTech将收购国际领先的人工智能和机器学习技术公司InstaDeap。 该交易包括总额约 3.62亿英镑的现金和BioNTech股份 ，以收购剩余InstaDeep公司100%的股份，不包括BioNTech已经拥有的股份。
BioNTech buys UK AI start-up InstaDeep in £562mn deal
WEBJan 10, 2023 · BioNTech has agreed to buy UK artificial intelligence start-up InstaDeep for up to £562mn in its biggest-ever deal, as the German company expands beyond the Covid-19 vaccine that transformed its...
BioNTech to Host AI Day as an Edition of its Innovation Series on ...
WEB4 days ago · MAINZ, Germany, September 17, 2024 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech”), alongside its artificial intelligence (“AI”) company InstaDeep Ltd. (“InstaDeep”), will host an AI Day, an edition of BioNTech’s “Innovation Series”, at 09:00 a.m. EDT (3:00 p.m. CEST) on Tuesday, October 1 st, 2024 in …
BioNTech to acquire Neon to strengthen global leadership
WEBJan 16, 2020 · --BioNTech and Neon Therapeutics, Inc. today announced that they have entered into a definitive merger agreement under which BioNTech will acquire Neon in an all-stock transaction valued at ...
BioNTech to Acquire Kite’s Neoantigen TCR Cell Therapy R&D …
WEBJul 19, 2021 · Kite’s neoantigen TCR platform enables the development of individualized TCR therapies that are custom designed to target individual neoantigens on a patient’s tumor. This program builds and further extends BioNTech’s leadership in individualized neoantigen targeting programs such as BNT122 (iNeST) and BNT221 (NEOSTIM).
Skip to content